Dilantin and metyrapone: a clinically significant example of enzyme induction.
D015065:17-Hydroxycorticosteroids / Q000032:analysis; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D003864:Depression, Chemical; D004721:Endoplasmic Reticulum; D004790:Enzyme Induction / Q000187:drug effects*; D004827:Epilepsy / Q000188:drug therapy; D004967:Estrogens / Q000009:adverse effects; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D006965:Hyperplasia; D007018:Hypopituitarism / Q000175:diagnosis; D008099:Liver / Q000201:enzymology / Q000473:pathology; D008797:Metyrapone / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006899:Mixed Function Oxygenases / Q000096:biosynthesis; D010634:Phenobarbital / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects*; D010901:Pituitary Function Tests; D011749:Pyrogens / Q000494:pharmacology; D051381:Rats
D015065:17-Hydroxycorticosteroids; D004967:Estrogens; D005965:Glucuronates; D011749:Pyrogens; D010672:Phenytoin; D000324:Adrenocorticotropic Hormone; D006899:Mixed Function Oxygenases; D010634:Phenobarbital; D008797:Metyrapone